26. March 2017

Aim: The therapeutic efficiency of a formulation will depend on various crucial parameters such as solubility of the drug, stability of the compound, excipients used in the formulation of finished dosage form, and the manufacturing technology used for the fabrication of finished dosage form. This research work is an attempt to enhance the solubility and dissolution rate by fabricating solid dispersion (SD) of the bosentan using hydrophilic polymers, soluplus, and kollidon VA 64. SDs of...

15. March 2017

Abstract The formulation of lipophilic and hydrophobic compounds is a challenge for the pharmaceutical industry and it requires the development of complex formulations. Our first aim was to investigate hot-melt extrudate microstructures by means of multifractal analysis using scanning electron microscopy imaging. Since the microstructure can affect solid dosage form performance such as mechanical properties, a second objective was to study the influence of the type of adsorbent and of the...

22. February 2017

Abstract Mannitol is a commonly used bulking agent in lyophilized formulations. It can crystallize into multiple solid forms during lyophilization thereby exhibiting phase heterogeneity and variability in product performance. In this manuscript, we studied the effect of cyclophosphamide (CPA), an anticancer drug, on the solid form of mannitol during lyophilization from aqueous solutions. Freeze-concentration studies were performed in the DSC while lyophilization was performed in a lab scale...

03. February 2017

ABSTRACT Co-processing is one of the ways to develop new excipients for the pharmaceutical industry. Co-processed excipients are a combination of established two or more excipients through physical mixing or co-process technology. Co-processed excipients has no change in chemical structure, it only changes physical properties of the final product. Co-processing technology could lead to formation of co-processed excipient with superior physical properties compared to simple physical mixtures of...

08. October 2016

Abstract The number of topical fungal infections is growing, mostly owing to immunosuppressive therapy. Several topical fungal infections, such as eye mycoses, can be treated by local administration of antimycotic drugs. One major group of the antifungal agents is triazole, such as voriconazole (VCZ), which is used as the first line treatment of aspergillosis. A disadvantage of VCZ is its low water solubility making the drug difficult to administer in a liquid preparation. The lipid-based...

16. May 2016

Paracetamol (PAR), phenylephrine hydrochloride (PHE) and chlorpheniramine maleate (CPM) are commonly used in clinical practice as antipyretic and analgesic drugs to ameliorate pain and fever in cold and flu conditions. The present work describes the use of thermal analysis for the characterization of the physicochemical compatibility between drugs and excipients during the development of solid dosage forms. Thermogravimetric analysis (TGA) and Differential Scanning Calorimetry (DSC) were used...

05. March 2016

This study explored the effect of nano-crystalline cellulose (NCC) on Meloxicam (MX) solid dispersion (SD) prepared by co-grinding technique compared to micro-crystalline cellulose (MCC) in presence of lactose. MX-tablets were prepared by direct compression of different co-ground SDs or physical mixtures. The solubility, dissolution, SEM and DSC of different preparations were studied. Flow-through cell apparatus (FTC) was used to study the dissolution of MX from tablets at pH 7.4. Generally,...

12. November 2015

24. June 2015

Formulating drugs in the amorphous form is an attractive and promising strategy to overcome the poorly water soluble challenge commonly encountered in the newly discovered drug. The active research in the investigation of the properties and performance of drugs in the amorphous form has revealed the major challenges in developing amorphous formulations into marketable products. The three main challenges are development of analytical techniques to characterise the amorphous formulations,...

12. June 2015

he principal component of many solid pharmaceutical formulations and indeed of dry powder inhalers, rather than being an active pharmaceutical ingredient (API), is most likely to be lactose. It is an excipient that fulfils a number of functions including those of diluent, flow-aid and API carrier. More Pulmonary Drug Delivery: Advances and Challenges Published Online: 29 MAY 2015 DOI: 10.1002/9781118799536.ch7